Serum ferritin in hematologic malignancies

Y. Matzner, A. M. Konijn, C. Hershko*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Serum ferritin was measured in a variety of hematologic malignancies at presentation, in remission following therapy, and in relapse. Ferritin was strikingly increased in all acute leukemias at presentation and in relapse, in the blastic crisis of CML, and in smouldering leukemia. Remission in both ALL and ANLL was associated with a reduction of serum ferritin, and this normalization was a function of remission duration. In the malignant lymphomas serum ferritin was related to tumor histology. Highest levels were found in Hodgkin disease and histiocytic lymphoma, normal levels in lymphocytic lymphoma, and intermediate levels in mixed histiocytic‐lymphocytic lymphoma. In all cases, remission was associated with normalization of serum ferritin. These correlations suggest that serum ferritin measurements may be of clinical usefulness in the initial evaluation and in the assessment of response to therapy in patients with acute leukemia and malignant lymphoma.

Original languageEnglish
Pages (from-to)13-22
Number of pages10
JournalAmerican Journal of Hematology
Volume9
Issue number1
DOIs
StatePublished - Aug 1980

Keywords

  • ferritin
  • Hodgkin disease
  • iron metabolism
  • leukemia
  • lymphoma

Fingerprint

Dive into the research topics of 'Serum ferritin in hematologic malignancies'. Together they form a unique fingerprint.

Cite this